ReviewEuropean respiratory review : an official journal of the European Respiratory Society2013
Severe refractory asthma: an update.
Review in European respiratory review : an official journal of the European Respiratory Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Reslizumab as add-on therapy in patients with refractory asthma.BMJ open respiratory research · 2020Trial
- Trial
- Trial
- Update on Pediatric asthma management: Recent advances.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
- Migrasomes derived from human umbilical cord mesenchymal stem cells: a new therapeutic agent for ovalbumin-induced asthma in mice.Stem cell research & therapy · 2025Article
- The new biologic drugs: Which children with asthma should get what?Pediatric pulmonology · 2024Review
- Nebulization of Hypoxic hUCMSC-EVs Attenuates Airway Epithelial Barrier Defects in Chronic Asthma Mice by Transferring CAV-1.International journal of nanomedicine · 2024Article
- A non-invasive strategy for suppressing asthmatic airway inflammation and remodeling: Inhalation of nebulized hypoxic hUCMSC-derived extracellular vesicles.Frontiers in immunology · 2023Article
- The Role of CD4International journal of molecular sciences · 2021Review
- Involvement of the epidermal growth factor receptor in IL-13-mediated corticosteroid-resistant airway inflammation.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2020Article
- Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment.BMC pediatrics · 2018Review
- The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis.Respiratory research · 2017Article
- Refractory asthma - An old disorder: Novel approaches for effective control.Medical journal, Armed Forces India · 2016Review
- Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.Journal of managed care & specialty pharmacy · 2016Observational
- Prevalence and severity of asthmatic symptoms in Grenadian school children: the Grenada National Asthma Survey.BMJ open · 2015Article
- The airway microbiome in patients with severe asthma: Associations with disease features and severity.The Journal of allergy and clinical immunology · 2015Article
- Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-κB (NF-κB) Signaling Pathway in Mice.International journal of molecular sciences · 2015Article
- PILL Series. The 'problematic' asthma patient.Singapore medical journal · 2015Article
- Altered Innate Immune Responses in Neutrophils from Patients with Well- and Suboptimally Controlled Asthma.Mediators of inflammation · 2015Article
- Nebulized perflubron and carbon dioxide rapidly dilate constricted airways in an ovine model of allergic asthma.Respiratory research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a heterogeneous disease in which adequate asthma control cannot be achieved in a substantial proportion despite currently available treatment possibilities. This subgroup has been defined as "severe refractory" asthma. Over the past years considerable progress has been made regarding a more exact definition of severe refractory asthma. A systematic approach to evaluate the asthma patient has been postulated. Further detailed classification into distinct phenotypes is ongoing to target the right treatment to the right patient. And, new therapeutic targeted treatment options are currently in development to provide possible new targets to improve disease state, symptoms and quality of life. This review will provide an update on the latest advancements with regard to all these domains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.